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Aims: Multiple sclerosis (MS) leaves a signature on the phosphorylation and thus proton binding capacity of
axonal neuroﬁlament (Nf) proteins. The proton binding capacity in a tissue is the major determinant for ex-
change between bound and free protons and thus the magnetisation transfer ratio (MTR). This study inves-
tigated whether the MTR of non-lesional white matter (NLWM) was related to the brain tissue concentration
of neuroﬁlament phosphoforms.
Methods: Unﬁxed post-mortem brain slices of 12 MS patients were analysed using MTR, T1 at 1.5 T. Blocks
containing NLWM were processed for embedding in parafﬁn and inspected microscopically. Adjacent tissue
was microdissected, homogenised and speciﬁc protein levels were quantiﬁed by ELISA for the Nf heavy chain
(NfH) phosphoforms, glial ﬁbrillary acidic protein (GFAP), S100B and ferritin.
Results: Averaged hyperphosphorylated NfH (SMI34) but not phosphorylated NfH (SMI35) levels were differ-
ent between individual patients NLWM. The concentration of hyperphosphorylated NfH-SMI34 correlated
with T1 (R=0.70, p=0.0114) and— inversely—with MTR (R=−0.73, p=0.0065). NfH-SMI35 was not cor-
related to any of the MR indices.
Conclusions: Post-translational modiﬁcations of axonal proteins such as phosphorylation of neuroﬁlaments
occur in NLWM and may precede demyelination. The resulting change of proton mobility inﬂuences MTR
and T1. This permits the in vivo detection of these subtle tissue changes on a proteomic level in patients
with MS.
© 2011 Elsevier Inc. Open access under CC BY license.Introduction
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license.(Lassmann et al., 2007; Trapp and Nave, 2008). The most obvious
pathological ﬁnding in MS brain tissue is focal demyelination,
which may affect any part of the CNS (Chard and Miller, 2009).
New MS lesions may result in neurological symptoms and/or signs,
a clinical situation called “relapse”, though patients with non-
relapsing (primary or secondary progressive) MS also develop new
lesions, albeit less frequently (Petzold, 2008).
It is well known that areas of focal demyelination (MS lesions) repre-
sent only a fraction of MS pathology, with additional contribution of
non-lesional changes of brain parenchyma(Bjartmar et al., 2001;Howell
et al., 2010; Kutzelnigg et al., 2005; Zeis et al., 2008) and meninges
(Magliozzi et al., 2007). Both lesional and non-lesional MS brain paren-
chyma is affected by axonal damage (Albert et al., 2007; Kutzelnigg et
al., 2005; Peterson et al., 2001; Petzold, 2005; Trapp and Nave, 2008).
Neurodegeneration is the major cause of irreversible neurological dis-
ability in patients with MS (Trapp and Nave, 2008). The evolution of ax-
onal loss, however remains enigmatic (Moore et al., 2000). This is partly
because axonal damage in people with MS is difﬁcult to visualise in vivo
at a resolution conducive to the investigation of underlyingmechanisms.
Magnetisation transfer (MT) is a quantitative magnetic resonance
imaging (MRI) technique, based on the exchange of magnetisation
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bound to macromolecules (Tofts et al., 2003). Changes in MT derived
measures including the MT ratio (MTR) in the CNS of patients with
MS have been considered to reﬂect changes in the amount of myelin
(Barkhof et al., 2003; Schmierer et al., 2007). This has clearly been
shown in studies combining lesional and non-lesional brain tissue
(NLBT). The extent to which tissue changes may be detectable with
MTR applied to NLBT alone is less well known. In this study we inves-
tigated the association between MTR and proteomic alterations of
axons in MS non-lesional white matter (NLWM).
Based on histological studies it is well accepted that damage al-
ready occurs to axons in the NLWM (Lovas et al., 2000; Trapp et al.,
1998). The typical picture is that of irregular changes of the axonal di-
ameter and axonal end bulbs (Trapp et al., 1998). Immunohistochem-
ical studies suggest that protein phosphorylation increases, at least
for the neuroﬁlament heavy chain (NfH) and tau (Anderson et al.,
2008; Petzold et al., 2008; Schneider et al., 2004). These histological
and immunohistochemical data are consistent with changes on a pro-
teomic level (Dutta et al., 2006; Herrero-Herranz et al., 2008; Petzold
et al., 2008). Protein phosphorylation appears to be an important bio-
chemical mechanism by which axonal injury is mediated (Petzold et
al., 2008). Many of the well established mechanisms driving neurode-
generation (glutamate excitotoxicity, mitochondrial failure) are relat-
ed to Ca2+ inﬂux, activation of kinases and phosphorylation of NfH
(Akassoglou et al., 2002; Brownlees et al., 2000; Grant and Pant,
2000; Petzold, 2005; Schwarzschild et al., 1999; Xia et al., 1996).
An increase of NfH phosphorylation changes the charge depended
proton binding capacity of the protein. Non-phosphorylated NfH only
binds two protons (Chang et al., 2009). Phosphorylated NfH in con-
trast has the ability to bind up to 82 protons, a remarkable difference
(Chang et al., 2009). The biological relevance of NfH phosphorylation
in the MS brain is not known. On a proteomic level phosphorylation
of NfH causes radial extension of sidearms out of the dense polymer
structure. This is explained by charge repulsion and locally altered en-
tropic and electrostatic interactions of the neuroﬁlament network
(Kim et al., 2011; Petzold, 2005). Here we report preliminary evi-
dence that changes in the phosphorylation status of NfH, and hence
the proton binding capacity of the neuroﬁlament network, is detect-
able using MT imaging in MS NLWM.
Material and methods
This study was approved by the Joint Ethics Committee of the UCL
Institute of Neurology and The National Hospital for Neurology &
Neurosurgery, London, UK. The MRI data sets and parafﬁn embedded
tissue blocks were used alongside snap frozen samples of NLWM
obtained from the brain tissue in unﬁxed condition. The brain slices
had been donated by 10 women and 2 men with MS to the UK Multi-
ple Sclerosis Tissue Bank (MSTB) based at Imperial College London.
Brain slices used were collected from the MSTB within a mean of 17
(SD=6) hours post mortem. Demographic data including age, dis-
ease duration, course and brain weight were obtained from the case
records collected at the MSTB and based on information from the
same source. Disability was estimated using the expanded disability
status score (EDSS) scale (Kurtzke, 1983). Some of the MRI data sets
used in this study had been used previously to investigate changes
of MRI data in the white matter following ﬁxation (Moore et al.,
2000; Schmierer et al., 2008).
Tissue handling
In each case a coronal brain slice (≈1 cm thick) from one hemi-
sphere had been dissected at the level of the mamillary bodies, sealed
in a plastic bag and stored in a refrigerator at 2–8 ?C. Three hours be-
fore MRI brain slices were taken out of the fridge, carefully wrapped
in polyethylene ﬁlm and left to warm up to scanner roomtemperature (≈20? C). Immediately after MRI, samples of NLWM
(size=0.5–1 cm3) were obtained from the brain slices and snap fro-
zen in liquid nitrogen. Digital images of the brain slices were taken
showing the location where snap frozen samples had been obtained.
Thereafter, brain slices were immersed in 10% buffered formalin.
MRI scanning and parameter map calculation
Scans were acquired on a GE Signa Horizon Echospeed 1.5 T sys-
tem (General Electric, Milwaukee, WI, USA) using a birdcage head
coil. The MRI plane was positioned parallel to the coronal surface
and in the centre of each brain slice. The following data sets were ac-
quired using an imaging slice thickness of 5 mm, a ﬁeld of view (FOV)
of 24×24 cm2 and a matrix size of 256×256 (giving a pixel size of
0.94×0.94 mm2):
• 2D dual spin-echo (SE) proton density (PD)- and T2-weighted
(T2w) images with parameters TR=2000 ms and TE=30/120 ms,
respectively.
• 2D PD and T1w gradient echo images TR/TE/ﬂip angle=1500
ms/11 ms/45°and 36 ms/11 ms/45°, respectively), from which T1
maps were generated as previously described (Moore, 2003).
• 2D dual SE images (TR/TE1/TE2=1720 ms/30 ms/80 ms) obtained
with (Msat) and without (M0) a sinc shaped saturation prepulse ap-
plied 1 kHz off water resonance, from which MTR maps were calcu-
lated according to MTR=100×(M0−Msat)/M0 (Schmierer et al.,
2007).
Deﬁnition of ROI
All scans and maps were displayed on a Sun workstation (Sun
Microsystems, Mountain View, CA, USA) using DispImage (Grimaud
et al., 1996; Plummer, 1992). Areas of NLWM were deﬁned on T2w
SE images as areas of white matter that was free from hyper-
intense signal suggesting MS lesions. The absence of lesions in areas
where snap frozen samples had been obtained was conﬁrmed by vi-
sual inspection of the T2w scans using the digital images of brain
slices obtained in the dissection theatre as a reference. Accuracy of
the correspondence between areas of NLWM detected on MRI and
their histological substrates in brain slices were further enhanced
through the use of a previously described stereotactic procedure in
all cases (Schmierer et al., 2003).
Pathological procedures
Tissue blocks sized approximately 1.5×1.5×1 cm and containing
the areas of NLWM detected on MRI were dissected. The blocks
were cut in half using a 5 mm deep iron angle resulting in two blocks
of approximately 5 mm thickness each with the cutting plane corre-
sponding to the centre of the MRI plane. Blocks were processed for
embedding in parafﬁn and sections stained for haematoxylin &
eosin (H&E), Luxol-Fast blue (LFB) and Bielschowsky's silver impreg-
nation. Sections were inspected to conﬁrm no areas of demyelination
or remyelination (Brück et al., 2003; Schmierer et al., 2004) had been
sampled for protein extraction (see below).
Protein extraction
Snap-frozen blocks of brain tissue from MS cases were cut and re-
suspended at 1:5 g/mL in Tris-HCl buffer (100 mM Tris, pH 8.1 with
1% Triton X-100). A protease inhibitor cocktail (Sigma, P 8340) was
added in a dilution 1:100. Samples were homogenised on ice by son-
ication, triturated 3 times through 19 and 21 gauge needles and spun
at 20,000 g. In order to de-lipidise the sample diisopropyl ether was
added. After extensive mixing, the sample was spun at 20,000 g. The
supernatant was covered by a myelin layer. A needle was put through
Table 2
Correlation table of brain proteins with demographic data, brain weight, post-mortem
CSF pH and time delay from death to analysis (hours). The R-values are shown. The
Bonferroni corrected p-value for multiple comparisons (4 comparisons per variable)
is 0.0125.
Variable NfHSMI34 NfHSMI35 Ferritin S100B GFAP
Age −0.21 −0.03 −0.69⁎⁎ −0.48 −0.30
EDSS 0.19 0.14 0.14 0.04 0.13
Disease duration −0.40 −0.07 −0.54 −0.29 0.09
CSF pH −0.26 0.25 0.33 0.10 0.30
Brain weight 0.05 0.33 0.35 0.42 0.65⁎
interval 1 0.27 −0.50 −0.04 0.00 −0.49
interval 2 −0.08 −0.38 0.15 0.41 0.16
⁎ pb0.05.
⁎⁎ pb0.0125.
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ringe. The myelin layer and pellet were decanted.
Protein biomarker assays
Levels of NfH phosphoforms, ferritin, GFAP and S100B were quanti-
ﬁed using in-house ELISAs techniques as described (Green et al., 1997;
Keir et al., 1993; Petzold et al., 2003, 2004). All samples were analysed
in duplicates and repeated if the error between duplicates exceeded
10%. Here we adhere to a previously proposed nomenclature where
NfH captured by the monoclonal antibody SMI34 is indicated as
NfHSMI34 and captured by the monoclonal antibody SMI35 as NfHSMI35
(Petzold, 2005; Petzold et al., 2003). The precise binding epitopes of
these antibodies are not known. The binding of SMI34 is highly phos-
phate dependent and therefore related to the degree of NfH phosphor-
ylation. Total protein was determined using the Bio-Rad Protein assay
(Bio-Rad, Hemel Hempstead, UK).
Data analysis
All statistical and data analyses were carried out using SAS (version
9.1, SAS Institute, Inc., Cary, NC, USA). Correlation analysis was per-
formed using the Spearman correlation coefﬁcients followed by the
Bonferroni correction in case of multiple analyses. A p-value of b0.05
was accepted as signiﬁcant.
Results
Patient characteristics and quality of post-mortem material
The mean age of the patients was 56 years (SD: 14 years; range:
34–82); their mean disease duration was 23 years (SD: 10; range:
6–37). Brains were retrieved by the MSTB a mean of 17 h (SD: 6 h;
range: 9–28 h) after death. The brain slices were scanned 52 h (SD:
23; range: 23–103) after death.
The individual patients' characteristics are summarised in Table 1.
A total of 128 samples were analysed. The number of samples ana-
lysed per patient varied from 4 to 18 (Table 1).
Importantly, there were no signiﬁcant correlations of any of the
brain proteins with the delay from death to post-mortem or tissue
analysis (Table 2). There were no correlations between brain proteins
and the pH of the post mortem CSF. Similarly, brain proteins were not
correlated to age, years of disease duration and degree of disability
(Table 2). Table 3 summarises the concentration of all protein bio-
markers per mg of total soluble protein. The highest concentration
was observed for NfH SMI34 (median 2.7 μ?g/mg protein, calculating
to 0.0027% of total soluble protein. The corresponding NLWM T1 re-
laxation time was 661 ms with a MTR of 34.5 ms.Table 1
Subject characteristics. Duration is the disease duration in years. Interval 1 is time from
death to post-mortem and interval 2 time from death to MRI analysis in hours. The
number of tissue samples taken per patient is also provided.
Case Age Gender EDSS Duration Course Interval 1
(h)
Interval 2
(h)
Samples
#1 72 F 7 35 5 17.5 41.5 9
#2 49 F 9 14 2 16.5 44.5 18
#3 76 F 8.5 23 6 11 38 11
#4 52 M 7 24 6 13.5 23 11
#5 58 F 9 32 2 16.5 40 9
#6 82 F 8.5 37 2 15 77 8
#7 50 F 7.5 31 2 9 103 9
#8 34 F 9.5 12 2 12 33 4
#9 55 F 6.5 20 2 24 48 7
#10 44 F 9 16 2 18 83 18
#11 45 F 8.5 6 2 28 44 6
#12 56 M 8.5 29 6 25 48.5 18Light microscopy
Areas from which samples for protein extraction had been
obtained were free of de- or remyelinated lesions (Fig. 1A). In this
NLWM, some degree of axonal swelling was observed (Fig. 1B). The
irregular shape of axons from NLWM becomes more apparent at a
higher resolution (shown magniﬁed in Fig. 1C). There was a signiﬁ-
cant amount of gliosis throughout the analysed NLWM tissue.
Protein–protein relationship
Strong correlation between NLWM S100B and ferritin levels
(R=0.87, p=0.0002, data not shown). A weaker correlation was
found for NLWM S100B and GFAP levels (R=0.60, p=0.03, data not
shown). There was no correlation between NfH SMI34 and NfH SMI35
with each other or any of the other proteins.
Brain protein–MRI relationship
Representative 1.5 T MR images of post mortem MS brain slice are
shown in Figs. 2A–C. Fig. 2A shows the appearance of artefacts due to
ﬁxation of the brain slice on a cork board. These areas were not used
for analyses. The quantitative data for the T1 relaxation time and MTR
of the NLWM was summarised in Table 3. Signiﬁcant correlations
were detected between NfH SMI34 and T1 (R=0.70, p=0.01, Fig. 3A)
and— inversely—with theMTR (R=−0.73, pb0.01, Fig. 3B). No corre-
lations were detected between MRI indices and any other of the mea-
sured brain proteins.
Discussion
The main ﬁnding of this study was the strong correlation between
post-translational modiﬁcations of axonal proteins and two quantita-
tive MRI indices in NLWM as both T1 and — inversely — MTR were
strongly associated with the tissue concentration of hyperphosphory-
lated NfH (NfHSMI34).Table 3
Composition of NLWM.
Variable Median IQR
Brain proteins in μg/mg protein
NfHSMI34 2.7 1.9–4.9
NfHSMI35 1.6 1.4–1.9
Ferritin 1.6 0.8–2.9
S100B 2.0 1.3–2.9
GFAP 0.8 0.6–1.1
MRI indices in ms
T1 relaxation time 661 593–755
MTR 34.5 32.0–35.3
Fig. 1. Histology of non-lesional white matter. (A) The Luxol fast blue staining does not reveal any areas of de- or re-myelination of the analysed tissue blocks (×125). (B) There is
evidence for irregularities in axonal diameter (Bielschowsky, ×125), (C) better seen at higher magniﬁcation (Bielschowsky, ×1250).
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MTRwas shown to be a predictor ofmyelin content inMS brain provid-
ed lesionswere included in the analysis (Barkhof et al., 2003; Schmierer
et al., 2004, 2007, 2008). Earlier evidence that in MS lesions MTR pri-
marily reﬂects the presence or absence of axons (van Waesberghe et
al., 1999; van Walderveen et al., 1998) had been challenged by multi-
variate statistical analyses showing that the correlation between MTR
and axons was secondary to the primary association between MTR
and myelin content (Barkhof et al., 2003; Schmierer et al., 2004). The
signiﬁcant axonal damage and loss in demyelinated MS lesions (Trapp
et al., 1998) and hence themarked lesionalMTR reductionmay howev-
er mask detection of more subtle changes in NLWM. Of note, myelin in-
duces and controls Nf phosphorylation (Dewaegh et al., 1992; Petzold,
2005; Sanchez et al., 2000). Therefore the data on the relationship be-
tween myelin and MTR (Barkhof et al., 2003; Schmierer et al., 2004)
may also be interpreted as indirect evidence of changes in Nf
phosphorylation.
Given that MTR changes were also detected in areas that did not
show overt demyelination, the suggestion is plausible that a different
tissue component (or several thereof) may underlie MTR changes in
NLWM. Our data indicate that MTR (and T1) may reﬂect early post-
translational changes of the axonal architecture. An early feature of
these changes in MS is phosphorylation of Nf and tau proteins, shown
in cell-culture (Jackson et al., 2004), animal models (Anderson et al.,
2008; Schneider et al., 2004) and post-mortem tissue (Dutta et al.,
2006; Petzold et al., 2008; Trapp et al., 1998).
Irrespective of its speciﬁcity for certain tissue features, MTR has
been shown to be highly sensitive for subtle tissue alterations in the
CNS of pwMS outside MS lesions (Symms et al., 2004). Several groups
have reported a mild downward slope of MTR preceding by months
the acute blood brain barrier disruption that characterises new demye-
linating lesions in patients with MS (Fazekas et al., 2002; Filippi et al.,(A) (B)
Fig. 2.Magnetic resonance imaging of an exemplary post mortemMS brain slice. (A) T2 weig
indicate artefacts due to tooth picks with which tissue was ﬁxed to a cork board.1998; Goodkin et al., 1998). It is intriguing to hypothesise such early
MTR changes result, at least in part, from the switch in the phosphory-
lation status of axonal neuroﬁlaments as our data suggest.
The correlation between NfHSMI34 and T1 is consistent with (1) the
detected change in MTR in this study and (2) previous work showing
loss of compactness and organisation of the axonal cytoskeleton in MS
NLWM (Petzold et al., 2008), resulting in a larger free proton pool
(thus increasing T1).
Our data on NfH is in line with what others found for tau protein
(Anderson et al., 2008; Schneider et al., 2004). Neuroﬁlaments are
unique polyampholyte allowing for considerable change of charge and
structure (Petzold, 2005). As heavily phosphorylatedNf proteins branch
out into the intracellular space of axons this may inﬂuence the balance
between free and macromolecular bound protons, possibly by charge-
repulsion. Taken together the present data suggests that the MRI quan-
tiﬁable increase of proton mobility in NLWMmay be possible intracel-
lularly and due to post-translational modiﬁcations of NfH, likely also
tau and possibly other proteins. Protein-structurally the polyampholyte
NfH should be of particular interest to proton dependentmeasurements
such as MTR or T1. The charge of non-phosphorylated NfH is near neu-
tral (−2e)with negatively charged amino acids loosely binding protons
(Fig. 4A top). In contrast, the charge changes to−82e if fully phosphor-
ylated (NfHSMI34). Strongly positive charged phosphor (4+) now is
bound to the aminoacids in NfHSMI34. This leads to extension of the
NfH sidearms from about 35 nm (Fig. 4A, red chain) to 70 nm from
the core at an ionic strength of 10 mM (Fig. 4B, red chain) (Kim et al.,
2011). Additionally, the strong charge repulsive interactions between
neighbouring sidearm coronas (Beck et al., 2010) may increase the rel-
ative proportion of free protons compared to the non–phosphorylated
stage (Figs. 4A and B). Biochemically the densely wrapped composition
of myelin proteins do not permit such structural changes, nor domyelin
proteins have the polyampholyte features of Nf proteins. Additionally, in(C)
hted image, (B) T1 relaxation map, (C) magnetisation transfer ratio (MTR) map. Arrows
(A) (B)
Fig. 3. In NLWM (A) NfHSMI34 was correlated with T1 relaxation time (R=0.70, p=0.0114) and (B) inversely with magnetisation transfer ratio (MTR, R=−0.76, p=0.0065).
Fig. 4. Typically there is a balance between free protons and macromolecular bound protons. It is proposed that this balance is dependent on NfH phosphorylation (pink dots).
(A) Negatively charged aminoacids in dephosphorylated NfH (red), NfM (blue) and NfL (green) provide reversible binding sites for a large pool of free protons (yellow dots)
which upon magnetic stimulation move from the macromolecular bound to become free protons. This is reﬂected in a low T1 and high MTR (B) For hyperphosphorylated NfH
reversible proton binding sites are extensively covered by phosphate (P4+, pink dots). Subsequently there are relatively less protons bound to the semi-solid pool with a larger
proportion of free protons. Therefore the T1 increases and MTR decreases. The protein-structure model is based on in vivo data from patients with multiple sclerosis and was
adapted from (Kim et al., 2011).
238 A. Petzold et al. / Experimental Neurology 232 (2011) 234–239this study we only investigated light microscopic normal myelinated
areas which virtually excludes a relevant drop out of myelin. Instead
our data suggests that the phosphorylation related increased proton-
binding capacity of axonal proteins such as NfH are likely responsible
for the internally consistent changes of MTR and T1.
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